U.S. Markets closed

Array BioPharma Inc. (ARRY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.3400-0.05 (-0.60%)
At close: 4:00PM EDT

8.4186 0.08 (0.94%)
After hours: 4:17PM EDT

People also watch
  • Hey guys. Let's be kinder to each other ok? The bullying on all sides in here is getting tiresome. There is enough ugliness out there, no need for us to further it in here. Be well, be be fulfilled, be hopefully successful what ever your trade and most importantly may we find a/many cure(s)!
  • This really impresses potential investors when they read these immature replies between bruno and atlantic.
  • Nice rebound today. I bought more shares at $7.95 this morning. Nice opportunity to buy on the cheap.
  • no word on 797? mouse got his tongue or has the NEW BOD told him to keep his mouth shut for once. Atlantic you live boring life I can tell, SHORTY
  • Vanguard, State Street and Blackrock are index investors. They pay little attention to fundamentals of a company. ARRY has very interesting specialist pharma investors, like T Rowe, Fidelity, Redmile and Orbimed, as investors and they know the industry well.
    Big pharma are looking for new compounds. Today it cost a company around $2bn to bring a new product to the market. With so many products close to the finish line, I am surprised that ARRY is still independent. When they get the first buyout offer, there will be multiple firms (Astra Zeneca, Pfizer, BMS, Hoffman Laroche, Novartis, Merck come to mind) competing to acquire this company.
  • Atlantic smelly Cod you have to be the angriest investor here, tell us a little about yourself, SHORTY. Do you have small hands ? Has IR returned our calls ? Iv spoken to them 2x in the last 2 weeks
  • This Atlantic person is a real pos . He can't seem to stop himself from insulting people who don't share his views. Must not have too many friends.
  • FAT FREDDY, first off anybody who makes an investment based on a message board deserves to lose their money, I also have 5 acres for sale on the moon. Second off most retail investors here couldn't move this stock up or down with their measly 100-1000 shares. I'm not sure if you're smart enough, if you don't like a persons posts or opinions you can block their post from your wall. I hope to meet both you and smelly fish SHM this year.
  • It going to be a while before this stock pops again. Although the company will within the next two months probably file the nda for the combo therapy.....it is expected so it may not have much effect on the pps. Of course if there's a delay, that would definitely have an effect. If the fda decides that the combo therapy is "more effective without any safety issues" they may fast track it which of course would be very positive.Long term with approval, Arry could be a $20 stock just based on the combo therapy.
  • . Some jerkoff short sold 10 shares at 8.02 .
  • Announced February 21, 2017 that trial enrollment has been completed with Phase 2 data due 2H 2017. NDA filing late 2017 or early 2018. Late breaker ASCO June 3, 2017. Abstract LBA2501. THIS IS LOXO/ARRY
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio.

    • BioLargo’s 10Q states their Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence in first half of 2018
    • Sales and or licensing agreement/s could be very significant
    • Company is now commercializing several other disruptive products in large markets



    Clyra Medical | Make Life Better
  • Glad that Atlantic sold his 10 shares AH on Friday, guy is a tool
  • I am fine whether there is a buyout or not. I bought a lot when ARRY was around $3. In my view, this is one of the most undervalued companies compared to its pipeline. That is why so many successful and knowledgeable investors have significant stakes here.
  • Sucks to be a hated CEO on Wall Street............cried WOLF too many times.
  • What happened to the BIG talker regarding 797 spin off and Japanese partner ? How about delivering what you promise Mr so called CEO . How big is you're salary ? ALOT bigger than you deserve, I hope the institution band together to get you replaced ASAP. The shorting that's been going on are from the institutions in case you didn't know. They are tired of you blowing smoke up all the SH's #$%$
  • Heavy institutional ownership. Price targets 12-14.
  • Should Merck acquire ARRY ASAP? Merck wants to make sure Bini actually works with its KEYTRUDA as a combo. ARRAY latest Phase III results confirmed that Bini is highly effective as a combo. anti-PD-1 is a hot area that many other big pharma companies (Roche, Pfizer, Bristol Myers Squibb) are also in the race. If Merck waited to long, other big pharmas might want to take out ARRY first to prevent future competition for a combo treatment with ARRY's bini.
  • Fastest BS talking CEO on Wall Street, I will email them this morning
  • Harry Boxer has posted his Charts of the Day video on ARRY at TheTechTrader site noting: Array BioPharma Inc. (ARRY) had a big snapback after getting all the way up into the 13.40 range in Feb, and then it pulled down more than half. Wednesday’s pop with a breakaway gap went right up to the moving average, coiled the rally, and pulled back, closing up 1.41, or 20%, to 8.43, on 17.5 million shares traded. That’s the biggest volume since Sept when it had a big explosive day on drug news. Potentially, we’re going to watch Wednesday’s high at 9.24. If it gets through that, it will be running into the low teens. It has 7.2 days to cover.